Category: Innovation

  • Plan for Stakeholders, Not Scenarios

    Plan for Stakeholders, Not Scenarios

    You don’t build credibility in the moment. You risk it.

    In biopharma, few things are more fraught than the Phase 3 readout. Every stakeholder is watching. Investors modeling. Clinicians forming opinions. Patient advocacy organizations and families hoping for new options. The company’s own teams, from investor relations to medical affairs to marketing to market access to government affairs, are running their own parallel preparations, often without a shared view of what others are doing or what others know.

    The conventional response to that situation is scenario planning. Map the possible outcomes. Prepare statements for each. Establish a clearance process. Wait for the data.

    We took a different approach.

    Working with a global biopharma company ahead of a pivotal readout, we built an integrated stakeholder engagement plan. Not a crisis communications plan. Not a scenario-planning exercise. An engagement plan: a research-anchored assessment of eight stakeholder groups essential to the company’s long-term success, each mapped from where they stood at the start to where they needed to be by the time results were in hand, so that any outcome could be received in context rather than as a surprise.

    The plan mapped across the whole clinical development program. It included proactive engagement at every key landmark, the company’s and their stakeholders. Not announcements. Conversations and actions. Not managed messages. Shared progress.

    When the results came in and the trial outcome was negative, a coordinated plan was already in place across all eight. Not a siloed set of individual preparations. A single, integrated response built from a common foundation of stakeholder understanding.

    Even those most desperate for good news understood the outcome and held the company in high regard for bringing them along on the journey.

    That is not a communications outcome. It is a trust outcome. And it was built before the data existed.

    What Scenario Planning Gets Right, and What It Misses

    Scenario planning is a reasonable tool for managing what you say and anticipating operational choices. Readying for the unexpected, though sometimes predicted. It is not a plan for managing what your stakeholders experience.

    The distinction matters because stakeholders are not waiting for your announcement. They are forming opinions, gathering intelligence, comparing notes with each other, and building their own understanding of you and your situation based on everything they see, hear, do not hear from you and experience with you. By the time any landmark arrives, the context in which it lands has already been shaped.

    Scenario planning prepares the message and the corporate response. It does not build the relationship in which the message will be received.

    Every stakeholder audience arrives at the moment carrying assumptions, concerns, and relationship histories that no announcement can quickly undo.

    The integrated approach begins earlier. It begins with a question most organizations do not ask systematically: where does each critical stakeholder stand today, and what needs to be true about our relationship with them before the results arrive?

    What an Integrated Stakeholder Engagement Plan Actually Looks Like

    The work starts with a rigorous assessment of each stakeholder group: where are they now, in terms of understanding, confidence, and relationship with the company? What are their priorities and concerns? Who and what shapes their thinking? What are the key milestones on their own calendar that determine when they are most receptive and when they are most concerned? From that baseline, the plan maps each group forward to where they need to be, not in terms of what they believe about a specific outcome, but in terms of their relationship with the company’s science, their confidence in leadership’s judgment, and their understanding of what the program is designed to accomplish and why?

    The engagement points that connect those two positions are planned conversations, calibrated over time, that build the relationship the company will need. Every interaction is designed to move a stakeholder along a specific arc, from their current position to the one that serves both parties when the stakes are highest.

    This is not a messaging exercise. It is architecture. (Readers of Episode 2 will recognize the principle.)

    The Internal Alignment Problem Nobody Addresses Directly

    There is a second priority to this work that is rarely discussed with the directness it deserves: building organizational coordination and cross-functional capacity.

    In many organizations approaching a major milestone, investor relations, medical affairs, marketing, corporate affairs, and other functions are each running their own preparation. Each function has its own stakeholders, its own clearance requirements, its own institutional knowledge and engagement tradition. Each team is competent. Most are not coordinating.

    The result is a set of parallel preparations that converge at the same moment, the trial results and public disclosure, with different assumptions about the message, different levels of familiarity with the external stakeholder landscape, and different thresholds for what a successful response looks like. The tension in the planning war rooms is palpable because the interplay of stakeholder groups is rarely anticipated from the outset.

    Engagement by Design treats the alignment of internal functions as part of the stakeholder engagement strategy, not as a separate organizational problem to be solved later. The plan that guides communication must also be the plan that aligns internal teams and optimizes key actions. Not because internal alignment is a management virtue (though it is), but because stakeholders detect its absence. Investors talk to investigators. Patient advocates compare notes across the globe. Physicians build their expectations of a company’s current portfolio and what’s promising in the pipeline. A company that is not coordinated internally will eventually demonstrate that externally.

    Trust as a Measurable Corporate Asset

    The measure of an integrated stakeholder engagement plan is not how smoothly an announcement goes. It is the state of the relationship after an announcement, including when the news is not what anyone had hoped for.

    In the example here, stakeholders who had every reason to be disappointed by a negative trial outcome held the company in high regard. That is a specific, observable, consequential result. It reflects decisions made and actions taken months and years before the data existed. It is also the definition of what transparency looks like as a sustained corporate practice, not as a one-time gesture or a crisis communications posture.

    That reputation is not a byproduct of good work. It is the result of planned, proactive engagement, designed in advance, executed with discipline, and measured in the quality of the relationships it produces.

    The Question to Ask Before the Next Milestone

    The Impact Imperative returns to the same standard across every episode: does your engagement strategy produce evidence of impact, or only evidence of effort?

    For integrated stakeholder engagement, the questions are pointed. Do you know where each critical audience stands today, before the news arrives? Are your internal teams working from a shared understanding, or running parallel preparations that will converge at the last possible moment? When the outcome comes, whatever it is, will your stakeholders have the context to receive it, because you built that context with them over time?

    If the honest answer to any of those questions is uncertain, the architecture for sustained stakeholder engagement is worth examining before it is needed.

    That is where our work together begins.

  • JPM26 in Summary: Fat and Mostly Happy

    JPM26 in Summary: Fat and Mostly Happy

    The M&A Machine is Warming Up (Finally)

    Obesity: Still the Main Character

    Hot Zones That Also Carried Weight: Neurology & Oncology

    AI: From Hype Cycle to Deployment Reality

    Hospitals: The Unhappy Exception

    The Undercurrents: What Else Mattered

    The Vibe Check: Recovered, Not Euphoric

  • Strategic Engagement: Restoring Faith in Science and Medicine

    Strategic Engagement: Restoring Faith in Science and Medicine

    Science is advancing at breakneck speed. Immense accomplishments today. Immeasurable promise on the horizon. However, healthcare, biopharma, and health tech sectors stand at a critical juncture. The promise of groundbreaking therapies, diagnostics, and life-saving interventions has never been greater. But, beneath this veneer of progress lies a profound challenge: a widening chasm of public trust in science and innovation.

    Major global gatherings, such as the Geneva Science and Diplomacy Anticipator summit, reveal a paradox. Bold advances promise widespread benefits. However, public trust in life transforming science is declining. Today, trust in science can no longer be presumed—the consequences affect health, business, and society.

    Scientific achievements, no matter how profound, struggle for acceptance without intentional, empathetic engagement. As trust fails, clinical trial enrollment stalls, vaccine hesitancy rises, and misinformation drowns out credible science.

    These conditions have been in the making for decades. For scientific and medical communities, delivering health and cures were assumed wins, resulting in the public embraces and confidence. Facts, data, and peer-reviewed studies were believed to be the ultimate arbiters of truth and drivers of acceptance. However, the last decade has laid bare a stark reality: facts alone are insufficient to build and sustain public trust.

    But, there are solutions: A paradigm rooted in strategic communication and genuine engagement. It is both a moral imperative and a critical business advantage. Leaders at the forefront of health and innovation implementing create the foundation for business success.

    The Erosion of Trust: A Multi-Layered Problem

    The decline in public trust in science and healthcare stems from several interconnected factors:

    1. The Information Overload and Misinformation Deluge: The digital age has democratized information. It has also created a fertile ground for misinformation and disinformation. Digital algorithms amplify sensationalism over accuracy. Emotionally charged narratives often outweigh scientifically sound explanations, making it harder to distinguish myth from fact.
    2. Commercialization and Perceived Conflicts of Interest: Health care, medicines and new technologies are multi-billion-dollar industries. While innovation requires investment, this awareness often translates into skepticism about motives. Company profits, drug pricing, and opaque costs contribute to negative narratives that undermine the altruistic aims of medical advancement.
    3. The Slow Pace of Science vs. The Instant News Cycle: The scientific progress is incremental, characterized by hypotheses, experiments, peer review, and often, corrections. It is deliberative, measured and not always linear. This clashes with shortening attention spans and the 24/7 news cycle that features headlines, not thorough and persuasive dialogue.
    4. Historical Injustices and Systemic Inequalities: Many communities, particularly those historically marginalized, distrust medical institutions. This is deeply rooted in past exploitation and ongoing systemic inequalities in healthcare access and quality. This baggage actively shapes present day perceptions.
    5. Swirling Authorities: Changing opinions based on belief are now touted as public health information from US government institutions. This contradicts proven science and fuels conspiracy theories. Eroding trust in institutions leads many to seek information locally. They turn to their doctor, their pharmacist, and their friends and families.

    These factors create an environment where scientific achievements–no matter how breakthrough– struggle to gain broad acceptance.

    The Power of Strategic Communication and Engagement

    To rebuild trust, biotech, pharma, health tech and healthcare organizations must take a proactive approach. They should focus on strategic communication and genuine engagement. We need to rethinking how advance science and engage the public.

    Pillar 1: Humanizing Science and Scientists

    The public doesn’t trust institutions; they trust people:

    • Elevate Authentic Voices: Empower scientists, researchers, and clinical leaders to become articulate, empathetic communicators. Provide media training that focuses on message points, storytelling, active listening, and connecting with diverse audiences on a human level.
    • Share Personal Journeys: Encourage sharing the “why” behind the science. What motivated a researcher to pursue a cure for a rare disease? What personal experiences inform a clinician’s approach to patient care? These narratives build emotional resonance and bridge the gap between complex science and relatable human experience.
    • Community Immersion: Encourage scientists to step outside the lab and engage with local communities—at schools, community centers, and local events. These are opportunities for genuine dialogue, answering questions, and building relationships over time.

    When the public sees the human face of science, familiarity, understanding and appreciation grows.

    Pillar 2: Radical Transparency and Vulnerability

    In an age of skepticism, honesty, even about limitations, is a powerful authenticity:

    • Demystify the Scientific Process: Proactively explain and show how science works. Include the iterative nature of research. Highlight the scientific debate. Help the public understand that uncertainty is a feature, not a bug, of scientific progress.
    • Acknowledge Limitations and Evolution: When scientific understanding evolves (e.g., changes in public health guidance), explain why the recommendations have shifted, based on new data or a deeper understanding. Avoid presenting science as infallible; instead, highlight its self-correcting nature.
    • Plain Language Communication: Eliminate jargon. Use analogies, visuals, and straightforward language to explain complex concepts. Assume no prior knowledge and prioritize clarity over technical precision in public communication. Always with a KISS, Keep It Simple, Stupid.

    Transparency builds credibility. When organizations are open about both successes and challenges, they foster a trust-building environment.

    Pillar 3: Authentic and Inclusive Engagement

    Trust is a two-way street. Genuine engagement means listening as much speaking:

    • Community Advisory Boards (CABs): Establish and empower CABs composed of diverse community members. These boards should have a genuine role in shaping research questions, clinical trial design, and communication strategies. They ensure relevance and cultural appropriateness. Always listen critically as CABs reveal unique perspectives on problems and solutions.
    • Leverage Trusted Messengers: Partner with established, trusted leaders within specific communities (e.g., patient advocates, community organizers, local physicians). Empower these collaborators with accessible scientific information they can share within their networks, bringing their trusted endorsement along with it.
    • Active Listening and Feedback Loops: Create channels for stakeholder feedback and genuinely listen to concerns, questions, and criticisms. Demonstrate that this guidance is valued and shapes how your organization communicates and operates. Address misinformation directly but by providing clear, evidence-based corrections and context.

    Inclusive engagement transforms the public into active participants in the scientific journey, building deep, resilient trust.

    The Business Imperative: Why Trust Matters to Your Bottom Line

    For executives across health care and innovation ecosystems, these are strategic imperatives that directly impact business outcomes:

    1. Accelerated Clinical Trials: Trusted organizations find it easier to recruit diverse patient populations for clinical trials and accelerating drug development
    2. Increased Patient Adoption: Public trust leads to greater acceptance of new therapies, treatments, and health recommendations. This adherence drives better patient outcomes.
    3. Enhanced Brand Reputation and License to Operate: A strong reputation for trustworthiness builds resilience against crises. It also fosters a positive public perception through ethical conduct.
    4. Mitigation of Misinformation and Crisis Resilience: Organizations with established trust are better equipped to combat misinformation and navigate crises.

    Rebuilding trust is urgent—and also an opportunity. At The Engager Company, we design bespoke communication and engagement frameworks. These frameworks help healthcare leaders meet today’s trust challenges. They also unlock business performance.

    Ready to discuss tailored strategies for corporate communications, science communications, launches, or stakeholder engagement? Let’s partner for a trusted future.